Breaking News
Get 45% Off 0
🌊 NVIDIA ripple effect: Track AI stocks' response to chip giant's earnings
Explore AI Stocks

Stock Markets Analysis & Opinion

Contribute
Zacks Investment Research
ETFs To Gain/Lose If Fed Turns Hawkish For 2018 By Zacks Investment Research - Dec 11, 2017

All eyes are currently on the crucial two-day FOMC meeting slated to start today as the central bank is highly anticipated to raise interest rates by a quarter percentage point to 1.25-1.5% for the...

Alex Newman
Darling Ingredients Eyes Uncertain Future By Alex Newman - Dec 11, 2017

Darling Ingredients Inc (NYSE:DAR), a natural ingredient supplier trying to be one of the 21st century’s leading innovators, is eying an increasingly Uncertain future on the marketplace....

Zacks Investment Research
Look At The Latest PPI Data By Zacks Investment Research - Dec 11, 2017

As the Federal Open Market Committee (FOMC) joins together for Chairwoman Janet Yellen’s final meeting as the head of U.S. monetary policy, expectations are near 100% that the end result...

Zacks Investment Research
Unemployment Rate Remains At 17-Year Low: 5 Fund Picks By Zacks Investment Research - Dec 11, 2017

Following a strong show in November with an increase in job additions and a low jobless rate, the sentiment remains positive over U.S. job data. Job additions remained high last month, recovering from...

Zacks Investment Research
Accenture Hits 52-Week High On Acquisitions & Partnerships By Zacks Investment Research - Dec 11, 2017

Shares of Accenture Plc (NYSE:ACN) rallied to a 52-week high of $151.14 yesterday, eventually closing a bit lower at $150.69. Notably, the stock has returned 28.7% year to date, outperforming its...

Zacks Investment Research
Company News For Dec 12, 2017 By Zacks Investment Research - Dec 11, 2017

Shares of KMG Chemicals, Inc. (NYSE:KMG) gained 0.3% after reporting first quarter 2018 earnings of $0.83 a share, surpassing the Zacks Consensus Estimate of $0.63Shares of argenx SE (NASDAQ:ARGX) ...

Zacks Investment Research
Marriott (MAR) To Expand With 40 Luxury Openings Next Year By Zacks Investment Research - Dec 11, 2017

Marriott International, Inc. (NASDAQ:MAR) announced a solid expansion plan as part of which it will open 40 luxury hotels in 2018. Its future plan also includes opening 200 hotels in 25 new...

Zacks Investment Research
Bitcoin ETFs Are Back After Futures Launch By Zacks Investment Research - Dec 11, 2017

Bitcoin — the hottest trade of 2017 — is now easily available to individuals and businesses courtesy of the launch of the first futures contract on Chicago Board Options Exchange ...

Zacks Investment Research
Synopsys Boosts Portfolio With Black Duck Software Buyout By Zacks Investment Research - Dec 11, 2017

Synopsys, Inc. (NASDAQ:SNPS) recently completed the acquisition of Black Duck Software announced in November. Black Duck is a provider of solutions related to security and management of open source...

Zacks Investment Research
Top Ranked Momentum Stocks To Buy For December 12th By Zacks Investment Research - Dec 11, 2017

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 12th:Famous Dave's of America, Inc. (DAVE): This developer of restaurants has a Zacks...

Zacks Investment Research
PetroChina (PTR) Carries Out Internal Transfer Of 16 Blocks By Zacks Investment Research - Dec 11, 2017

Per Reuters, PetroChina Company Limited (NYSE:PTR) , a subsidiary of state-owned China National Petroleum Corporation (“CNPC”), recently conducted an internal transfer of mining rights...

Zacks Investment Research
Top Ranked Income Stocks To Buy For December 12th By Zacks Investment Research - Dec 11, 2017

Here are four stocks with buy rank and strong income characteristics for investors to consider today, December 12th:Sonoco Products Company (SON): This consumer packaging products manufacturer has...

Zacks Investment Research
Spark Therapeutics Stock Plunges On Hemophilia Therapy Data By Zacks Investment Research - Dec 11, 2017

Spark Therapeutics’ (NASDAQ:ONCE) shares plunged 35% on Dec 11 as investors were disappointed with the data from a phase I/II study evaluating its gene therapy candidate, SPK-8011, for...

Continue with Apple
Continue with Google
or
Sign up with Email